Who
David S. Simmons
Director
Company insider
Files Form 4 as: Director, Viatris; Chief Executive Officer, Ppd; Director, Accendra Health; Business Unit President, Pfizer.
In numbers
- Trades disclosed
- 105
- Buys
- 5
- Sells
- 3
- Bought
- $1.2M
- Sold
- $8.0M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 31 Dec 2010
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $38K2,117 at $17.72 | filing |
| 30 Jun 2026filed 1 Jul 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $38K2,362 at $15.88 | filing |
| 30 Jun 2026filed 1 Jul 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $38K2,362 at $15.88 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —22,820 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —22,820 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —523.04 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —524 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —22,820 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —523.04 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —22,820 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —524 at $0.00 | filing |
| 3 Nov 2025filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Bought | $2,221213 at $10.43 | filing |
| 3 Nov 2025filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Bought | $2,222213 at $10.43 | filing |
| 27 Aug 2025filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Bought | $2,981286 at $10.42 | filing |
| 27 Aug 2025filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Bought | $2,980286 at $10.42 | filing |
| 11 Aug 2025filed 13 Aug 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —22,820 at $0.00 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code D | $75.2M2,318,799 at $32.45 | filing |
| 8 Dec 2021filed 8 Dec 2021 | Ppdoption or derivative | SEC FORM 4 Code A | —385,441 at $0.00 | filing |
News
Viatris' Dividend Has Room to Grow, but Will Management Deliver?VTRS · insidermonkey.com · 19 Oct 2026Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of PresbyopiaVTRS · prnewswire.com · 16 Oct 2026Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff?VTRS · insidermonkey.com · 9 Oct 2026
0 headlines in the last 90 days name David S. Simmons; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.